MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 137 filers reported holding MERSANA THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,173 | -61.4% | 17,459 | 0.0% | 0.00% | – |
| Q2 2023 | $57,440 | +14.1% | 17,459 | +42.6% | 0.00% | – |
| Q1 2023 | $50,335 | -29.9% | 12,247 | 0.0% | 0.00% | – |
| Q4 2022 | $71,767 | +46.5% | 12,247 | +68.6% | 0.00% | – |
| Q3 2022 | $49,000 | +44.1% | 7,262 | 0.0% | 0.00% | – |
| Q2 2022 | $34,000 | +17.2% | 7,262 | 0.0% | 0.00% | – |
| Q1 2022 | $29,000 | -52.5% | 7,262 | -26.1% | 0.00% | – |
| Q4 2021 | $61,000 | -35.8% | 9,826 | -2.6% | 0.00% | -100.0% |
| Q3 2021 | $95,000 | -30.7% | 10,092 | +0.1% | 0.00% | 0.0% |
| Q2 2021 | $137,000 | -14.9% | 10,081 | +1.3% | 0.00% | 0.0% |
| Q1 2021 | $161,000 | -16.6% | 9,947 | +37.0% | 0.00% | 0.0% |
| Q4 2020 | $193,000 | +82.1% | 7,262 | +28.0% | 0.00% | 0.0% |
| Q3 2020 | $106,000 | -20.3% | 5,674 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $133,000 | – | 5,674 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
| Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
| Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
| Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
| Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
| DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |